# Finite Treatment of Hepatitis Delta With Bulevirtide: Identification of Biomarkers Associated With Sustained Control of HDV Infection

> **NCT06603311** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Hannover Medical School** · enrollment: 20 (estimated)

## Conditions studied

- Compensated Liver Disease (Disorder)
- Hepatitis D, Chronic

## Interventions

- **OTHER:** Stop Treatment with Bulevertide in patients with compensated liver disease and chronic HDV infection

## Key facts

- **NCT ID:** NCT06603311
- **Lead sponsor:** Hannover Medical School
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-30
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06603311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06603311, "Finite Treatment of Hepatitis Delta With Bulevirtide: Identification of Biomarkers Associated With Sustained Control of HDV Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06603311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*